Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Cancer drug enters clinical trials based on a false mechanism

A cancer drug currently being tested in patients appears to have entered clinical trials based on...

Russia insists there is "no plague case" following lab worker death

Russian health authorities say there is no evidence that pneumonic plague played a part in the...

Scientists 'reprogram' tumour-supporting immune cells

The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...

Content from other channels on our network

Conviction and $20K fine follows "serious and prolonged" offending by former podiatrist

Supagas acquires Heeson Medical

Why digital resilience is becoming critical in aged care

Rapid-response discharge model targets bed block

A Good Cleaning Schedule: Best Practices for Healthcare Facilities

Testing Profinet I/O devices without a dedicated PLC

CCEP's $39.7m can line upgrade in Perth increases capacity 40%

Cybersecurity and digitalisation for Zimbabwe platinum mine

ENEOS opens Direct MCH large‍-‍scale demonstration plant in Brisbane

ARENA funds manufacturing of solar construction robots

Study assesses recycled content use in home builds

Smart bin receives 2026 Australian Good Design Award

Industrial electricity costs could halve by sharing infrastructure

Epson MD serves meals for CEO CookOff

AI solar smart bins to end Vic fixed-route rubbish runs